Literature DB >> 15130080

Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial.

Marilene B Alves1, Ana C F Motta, Waldenise C Messina, Dante A Migliari.   

Abstract

OBJECTIVE: To evaluate the efficacy of oral moisturizing gel (Oral Balance) in xerostomic patients with primary Sjögren's syndrome (SS). METHOD AND MATERIALS: Twenty-one xerostomic patients with primary SS were subjected to a single-blind trial in which the efficacy of Oral Balance gel in reducing xerostomia and xerostomia-related oral symptoms was compared with that of a placebo. Both gels were packaged identically and were indiscernible in appearance and taste. Xerostomia was confirmed for all the patients through measurement of stimulated whole saliva. Patients began using the Oral Balance gel three times a day for 90 days, and were then switched to a gel placebo to be used in the same way for the same length of time. Clinical response was evaluated through the patients' subjective assessment (improved, worsened, or unaltered) of both gels.
RESULTS: Neither the Oral Balance gel nor the gel placebo affected the salivary output of the patients. The Oral Balance gel presented a substantial statistically significant advantage in the control of burning mouth, mastication, and swallowing. No statistically significant relief of the isolated sensation of oral dryness was established.
CONCLUSION: Oral Balance is a useful tool in the management of dryness-related oral symptoms in primary SS, but there is room for enhancing the overall properties of topical preparations designed to reduce oral complaints in xerostomic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15130080

Source DB:  PubMed          Journal:  Quintessence Int        ISSN: 0033-6572            Impact factor:   1.677


  9 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

Review 2.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

3.  Evaluation of the clinical efficacy of Biotène Oral Balance in patients with secondary Sjögren's syndrome: a pilot study.

Authors:  Ardita Aliko; Adem Alushi; Argjend Tafaj; Ramazan Isufi
Journal:  Rheumatol Int       Date:  2011-09-07       Impact factor: 2.631

4.  The relationship between the severity of oral dryness and the use of dry-mouth interventions by various subgroups of dry-mouth patients.

Authors:  Z Assy; H S Brand; C P Bots; F J Bikker
Journal:  Clin Oral Investig       Date:  2022-01-10       Impact factor: 3.573

5.  [Liposomal local therapy as treatment for sicca symptoms in patients with primary Sjögren's syndrome].

Authors:  B Hofauer; M Bas; N Manour; A Knopf
Journal:  HNO       Date:  2013-11       Impact factor: 1.284

6.  The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study.

Authors:  Esin Alpöz; Pelin Güneri; Gonca Onder; Hülya Cankaya; Yasemin Kabasakal; Timur Köse
Journal:  Clin Oral Investig       Date:  2007-11-14       Impact factor: 3.573

Review 7.  Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands.

Authors:  Imran Nizamuddin; Peter Koulen; Carole P McArthur
Journal:  Int J Mol Sci       Date:  2018-09-13       Impact factor: 5.923

8.  Protease inhibitor concentrations in the saliva of individuals experiencing oral dryness.

Authors:  Kenkichi Yamamoto; Makiko Hiraishi; Mai Haneoka; Hidetake Fujinaka; Yoshitaka Yano
Journal:  BMC Oral Health       Date:  2021-12-20       Impact factor: 2.757

Review 9.  Chemosensory dysfunction in primary Sjögren's syndrome: a topical review.

Authors:  C Foguem; R Seror; M Gosset
Journal:  Clin Rheumatol       Date:  2022-09-05       Impact factor: 3.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.